Tarsus Pharmaceuticals Inc. (TARS), a biopharmaceutical company developing therapeutic candidates to address highly prevalent diseases with limited treatment options, has two clinical trial catalysts to watch.
Topline data from the company's Galatea study and Carpo study are due this quarter.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com